FIND & NDWG SYMPOSIUM, 24 OCTOBER 2018

SPEAKERS BIOS

DR ERIC GOOSBY
Eric Goosby has dedicated his professional life to fighting Tuberculosis and HIV/AIDS as a clinician, researcher and policy maker. After serving in the US State Department as Ambassador-at-Large and US Global AIDS Coordinator, he returned to the University of California, San Francisco where he still serves as Professor of Medicine and Director for Global Health Delivery and Diplomacy. In 2015 Dr. Goosby was appointed by UN Secretary-General Ban Ki-moon as the UN Special Envoy on Tuberculosis. In his capacity as Special Envoy, Dr. Goosby works toward raising the profile of the fight against TB and promoting the adoption, financing and implementation of the World Health Organisation’s global End TB Strategy.

SESSION 1: UPDATES ON THE GLOBAL TB DIAGNOSTICS PIPELINE (14:00-15:00)

DR CLAUDIA DENKINGER, FIND
Claudia Denkinger is Head of TB Programme at FIND. She is a clinician specialized in infectious diseases and worked in non-governmental organizations in HIV and tuberculosis care in South Africa and South America. Her postdoctoral work focused on TB epidemiology and impact assessment, as well as mathematical modeling of TB diagnostics.

DR JIM GALLARDA, BMGF
Jim Gallarda serves as a Senior Program Officer, Diagnostics with the Bill & Melinda Gates Foundation in Seattle. He has a strong background in both science and industry with more than 20 years in developing in vitro diagnostics at Abbott Laboratories, Roche Molecular Systems, and Novartis Pharmaceuticals. He has extensive experience in blood screening infectious disease assay development and has overseen multiple teams developing immunodiagnostic & PCR systems for infectious diseases.

DR CHRISTOPHER GILPIN, WHO
Chris Gilpin has over twenty years’ experience as a Microbiology Laboratory Scientist managing diagnostic laboratories in Australia and the Middle-East. Chris holds a PhD in TB molecular diagnosis and epidemiology and a Master of Public Health focused on tuberculosis and migration. Chris is currently employed by the World Health Organization as the Senior Scientist in the Laboratories, Diagnostics and Drug Resistance Unit of the Global TB Programme and is leading the development of policy guidance and technical documentation for new TB diagnostic technologies.
SESSION 2: PANEL DISCUSSION - A NEW PRIORITY FOR TB DIAGNOSIS: ACTIVE CASE FINDING STRATEGIES TO CATALYSE COUNTRY EFFORTS (15:00-16:15)

DR LIZ CORBETT, LSHTM
Liz Corbett is a Wellcome Trust Senior Fellow and a Clinical Epidemiologist with the London School of Hygiene and Tropical Medicine, based full time in Blantyre, Malawi. Her main research interests concern HIV and TB in HIV prevalent populations from the public health perspective, with a focus on primary care and community level diagnostic interventions. She also works closely with the World Health Organization.

DR SARABJIT CHADHA, FIND INDIA
Sarabjit Chadha is the Regional Technical Director at FIND India. He is a clinician by training with over 15 years’ experience of clinical and programmatic management of Tuberculosis (TB), including drug resistance TB. His other areas of expertise and interest are vector borne diseases, infection control and health system strengthening. He is the Chair of the ‘WHO Regional Drug-Resistant TB Advisory Group’ for the South East Asian Region and co-chair of the ‘TB and Prison sub-group’ of The Union.

PROF KEERTAN DHEDA, UNIVERSITY OF CAPE TOWN
Prof. Keertan Dheda leads the Centre for Lung Infection and Immunity at the University of Cape Town and is Professor of Respiratory Medicine, Director of the Centre for Lung Infection and Immunity (CLII), and Head of the Division of Pulmonology in the Department of Medicine at the University of Cape Town. He is a Visiting Professor at University College London and holds an Honorary Professor appointment at the London School of Hygiene and Tropical Medicine.

DR TITUS DIVALA, UNIVERSITY OF MALAWI
Titus Divala is a Public Health Physician and Researcher with University of Malawi’s Helse Nord TB Initiative. His main research interest is in TB screening at primary care clinics, including the optimal role of routine use of broad-spectrum antibiotics as part of the diagnostic evaluation for presumptive sputum-negative TB patients with and without underlying HIV infection. Titus was himself treated for pleural TB during his medical internship, leaving him with a minor chest X-ray abnormality and a special interest in TB diagnostics.

DR HAMIDAH HUSSAIN, IRD GLOBAL
Hamidah Hussain is a public health professional with over two decades of experience in running global health delivery programs and epidemiological research. She is the Program Director of the TB and drug-resistant TB (DR-TB) program based at the Indus Hospital in Karachi. Hamidah trained in medicine at the Aga Khan University in Karachi and has an MSc in Health Policy, Planning and Financing from the London School of Hygiene and Tropical Medicine.

DR NESTANI TUKVADZE
Nestani Tukvadze has been working at the National Center for Tuberculosis and Lung Diseases (NCLTD) in Tbilisi, Georgia for over 14 years. She was appointed as a Director of Research in August 2012. She serves as a PI and Co-I for several international research projects including those with FIND. Additionally she is a technical advisor for WHO EURO and has performed consultations and TB Program reviews in 17 countries of the WHO European Region.
SESSION 3: NDWG TASK FORCES - ACCELERATING DEVELOPMENT OF NEW TESTS TO END TB (16:15-16:45)

DR CAMILLA RODRIGUES, HINDUJA HOSPITAL
Dr Camilla Rodrigues is currently a Consultant Clinical Microbiologist and Chair of Infection control at the P D Hinduja Hospital in Mumbai. She is a member of several International and National Expert Committees. She has 290 publications and has conducted 90 Research projects with focus area being TB.

TOBIAS BROGER, FIND
Tobias is leading the development of biomarker-based assays in multiple FIND projects and coordinates FIND’s technology scouting and partner selection activities. Tobias holds a Master of Science in Engineering and a diploma in Biological Chemistry from Zurich University of Applied Sciences. He has over 10 years of cumulative experience in biomedical R&D, including the management of interdisciplinary industry projects, product development and the planning and execution of clinical feasibility and evaluation trials.